Table 2.
Performance evaluation of the CapitalBio™ DNA microarray for MDR-TB cases compared with the standard drug sensitivity testing (DST) method for the 671 samples
| Conventional drug susceptibility testing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CapitalBio™ DNA microarray | MDR-TB (%) | non-MDR (%) | Total No. | Sensitivity (%) | Specificity (%) | AR | PPV (%) | NPV (%) | Kappa |
| 74.1 | 99.8 | 93.6 | 99.2 | 92.4 | 0.81 | ||||
| MDR-TB | 120 (74.1) | 1 (0.2) | 121 | ||||||
| Non-MDR | 42 (25.9) | 508 (99.8) | 550 | ||||||
| total | 162 | 509 | 671 | ||||||
Abbreviations: PPV positive predictive value, NPV negative predictive value, AR agreement rate